Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Momo25on Dec 02, 2022 11:02am
124 Views
Post# 35146354

RE:Heads need to role

RE:Heads need to roleIncompetency + lack of credibility., this is how we can qualify the board of TH. The only progress they made in the last 2 years is lie over lie. Unbeatable in this domain! I think a lawsuit is worth it to get the whole board jailed. We have lost a huge amount of our wealth. They have to pay for it in a certain way.
Having said that. I hope the 2 programs Nash and Oncology will be cancelled not delayed to avoid burning more and mpre cash for nothing. This month will be the worst for the SP because of the inevitable declaration of capital that many will be forced to. Starting 2023, the market will be focusing on the legacy drugs. Hopefully  Egrifta and Trogarzo, without oncology and Nash programs in perspective, will push the SP to abou $3.

<< Previous
Bullboard Posts
Next >>